Drug intelligence / Profile preview

RIG-1250

Development stage: Preclinical
Lead developer: ReIGNITE Therapeutics
Modality: Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
Administration: Intravenous

Overview

RIG-1250 is an engineered oncolytic vaccinia virus developed by ReIGNITE Therapeutics for the treatment of solid tumors and metastatic cancer. Developed using a directed evolution platform, the virus is designed for intravenous (IV) administration and exhibits a natural tropism for cancer cells, as vaccinia virus lacks a specific receptor for cell entry. RIG-1250 is "armed" with multiple immunostimulatory transgenes intended to enhance anti-tumor immunity while the virus preferentially infects and lyses cancer cells. It is currently in the IND-enabling stage of development.

Beyond the preview

Go deeper on RIG-1250.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RIG-1250.

Explore the full profile